Good grief! When I hear this two-word phrase, I often associate it with the cartoon character Charlie Brown. Otherwise, the words “good” and “grief” seldom seem to belong together. What do you do with grief amid the holiday season? If you’ve been reading my columns for some time,…
The first patient has been dosed in a Phase 2b clinical trial of Endeavor Biomedicines’ investigational oral therapy ENV-101 (taladegib) in people with idiopathic pulmonary fibrosis (IPF). WHISTLE-PF (NCT06422884) seeks to enroll around 200 adults in 14 countries. The first patient was dosed in Australia. The study’s launch…
Welcome to December. Wait, what? How is it December? Time seemed to move in slow motion during the height of the COVID-19 pandemic, and now it’s already the end of 2024. In 1974, the Rolling Stones released “Time Waits for No One.” One line sums it up: “Time…
Families will gather this week to celebrate Thanksgiving here in the U.S. But how do you safely navigate a large family gathering when colds, the flu, and COVID-19 are all circulating? When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in 2017, a lot changed in my world.
The Pulmonary Fibrosis Foundation (PFF) has launched “PF Basics: Info for Newly Diagnosed Patients,” a new educational program to help patients with pulmonary fibrosis (PF) and interstitial lung disease get answers to the most pressing questions about their disease after a recent diagnosis. “We heard from patients and caregivers…
Since my diagnosis of idiopathic pulmonary fibrosis (IPF) in 2016, I’ve learned to manage my emotions about my illness. However, there are a few circumstances that make it nearly impossible for me to control how I feel, often causing me to erupt with rage and anger. One of those…
Do you know what a hack is? It’s a way of doing something more simply, efficiently, or effectively. Throughout my journey living with idiopathic pulmonary fibrosis (IPF), I’ve found a number of hacks that make my life easier. When I was diagnosed with IPF in January 2017, I…
MNKD-201, Mannkind’s inhaled formulation of nintedanib for treating idiopathic pulmonary fibrosis (IPF), was found to be safe and well tolerated in a Phase 1 clinical trial involving healthy volunteers — meeting the study’s primary goal. The trial’s results also showed that participants did not experience the typical adverse…
Watching the U.S. elections last week was an exercise in mental health awareness, as is any activity in which the outcome is greeted with mixed reactions and emotions. The refrain from Carly Simon’s 1971 song “Anticipation” came to mind as I was laying out this column: “Anticipation, anticipation/ Is…
CAL101, an investigational therapy with the potential to treat pulmonary fibrosis, showed a favorable safety and pharmacological profile in a Phase 1 clinical trial, according to results announced by Calluna Pharma, its developer. “These results are an important step forward in the development of our lead asset, CAL101,…
Get regular updates to your inbox.
